Clinicopathological analysis of primary non-Hodgkin’s lymphoma of the female reproductive system
Hou Xiaorong, Chang Xiaoyan, Chen Jie, Hu Ke, Zhang Fuquan
Department of Radiation Oncology (Hou XR,Hu K,Zhang FQ),Department of Pathology (Chang XY,Chen J),Peking Union Hospital,Chines Academy of Medical Sciences,Peking Union Medical College,Beijing 100730,China
Abstract：Objective To retrospectively analyze the clinical pathological features and treatment outcomes of primary non-Hodgkin’slymphoma (NHL) of the female reproductive system. Methods A retrospective analysis was performed on the clinical data of 28 patients with primary NHL of the female reproductive system who were admitted to our hospital from 1990 to 2016. The lymphomas were classified and staged based on the WHO histological classification and the Ann Arbor staging system,respectively. Of the 28 patients,18(64%) underwent surgery,27(96%) received chemotherapy, and 8(29%) received radiotherapy. The Kaplan-Meier method was used to calculate survival rates. Results The 5-year follow-up rate was 86%.The median age was 56.5 years (13-80 years). The ovary was involved in 11 patients (39%). The lymphoma was staged as IVE in 18 patients (64%).The most common pathological type was diffuse large B-cell lymphoma. The median survival time was 23.5 months. The 1-, 3-, and 5-year overall survival rates were 89%, 74%, and 59%, respectively. Conclusions Primary NLH of the female reproductive system is an extremely rare neoplastic disorder with no typical clinical symptoms and mostly diagnosed in advanced stage. The combined treatment with surgery,chemotherapy, and radiotherapy plays an important role in the treatment of the disorder.
Hou Xiaorong,Chang Xiaoyan,Chen Jie et al. Clinicopathological analysis of primary non-Hodgkin’s lymphoma of the female reproductive system[J]. Chinese Journal of Radiation Oncology, 2018, 27(2): 161-164.
[1] Ganovska A,Kovachev S.Non-Hodgkin′s lymphoma of the female genital system—a literature review[J].Akush Ginekol (Sofiia),2015,54(3):17-23. [2] Kosari F,Daneshbod Y,Parwaresch R,et al. Lymphomas of the female genital tract:a study of 186 cases and review of the literature[J].Am J Surg Pathol,2005,29(11):1512-1520. [3] Wei WX,Huang JJ,Wang Y,et al. Primary female genital system lymphoma:a single institution′s experience over 10years[J].HematolOncol,2014,32(3):162-164.DOI:10.1002/hon.2118. [4] Ahmad AK,Hui P,Litkouhi B,et al. Institutional review of primary non-hodgkin lymphoma of the female genital tract:a 33-year experience[J].Int J Gynecol Cancer,2014,24(7):1250-1255.DOI:10.1097/igc.0000000000000201. [5] Lagoo AS,Robboy SJ.Lymphoma of the female genital tract:current status[J].Int J Gynecol Pathol,2006,25(1):1-21. [6] Vang R,Medeiros LJ,Ha CS,et al. Non-Hodgkin′s lymphomas involving the uterus:a clinicopathologic analysis of 26 cases[J].Mod Pathol,2000,13(1):19-28. DOI:10.1038/modpathol.3880005. [7] Mouhajir N,Diakite A,Toulba A,et al. Primary Non-Hodgkin′s Lymphoma of the Uterine Cervix:Case Report of Long-Term Survival Patient[J].J Obstet Gynaecol India,2014,64(Suppl 1):145-147. DOI:10.1007/s13224-013-0483-2. [8] Mandato VD,Palermo R,Falbo A,et al. Primary diffuse large B-cell lymphoma of the uterus:case report and review[J].Anticancer Res,2014,34(8):4377-4390. [9] Monterroso V,Jaffe ES,Merino MJ,et al. Malignant lymphomas involving the ovary. A clinicopathologic analysis of 39 cases[J].Am J Surg Pathol,1993,17(2):154-170. [10] Singh L,Madan R,Benson R,et al. Primary non-Hodgkins lymphoma of uterine cervix:acase report of two patients[J].J Obstet Gynaecol India,2016,66(2):125-127. DOI:10.1007/s13224-014-0647-8. [11] Chokoeva A,Tchernev G.Malignant lymphomas of the vulva-diagnosis and therapy[J].Akush Ginekol (Sofiia),2015,54(3):28-33. [12] Jordanov A,Hinkova N,Ivanov I,et al. Primary vaginal non-hodgkin lymphoma—a case report and review from the literature[J].Akush Ginekol (Sofiia),2015,54(5):47-48. [13] Anagnostopoulos A,Mouzakiti N,Ruthven S,et al. Primary cervical and uterine corpus lymphoma:a case report and literature review[J].Int J Clin Exp Med,2013,6(4):298-306. [14] Hollender A,Kvaloy S,Lote K,et al. Prognostic factors in 140 adult patients with non-Hodgkin′s lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis[J].Eur J Cancer,2000,36(14):1762-1768. [15] Yoshida S,Morii K,Watanabe M,et al. Characteristic features of malignant lymphoma with central nervous system involvement[J].Surg Neurol,2000,53(2):163-167. [16] Herrlinger U,Glantz M,Schlegel U,et al. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma:what we know,and how we can find out more[J].Semin Oncol,2009,36(4 Suppl 2):S25-34.DOI:10.1053/j.seminoncol.2009.05.004. [17] Yamamoto W,Tomita N,Watanabe R,et al. Central nervous system involvement in diffuse large B-cell lymphoma[J].Eur J Haematol,2010,85(1):6-10.DOI:10.1111/j.1600-0609.2010.01438.x. [18] dos Santos LV,Lima JP,Lima CS,et al. Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis[J].BMC Cancer,2012,12(?):288.DOI:10.1186/1471-2407-12-288. [19] Signorelli M,Maneo A,Cammarota S,et al. Conservative management in primary genital lymphomas:the role of chemotherapy[J].Gynecol Oncol,2007,104(2):416-421.DOI:10.1016/j.ygyno.2006.08.024. [20] Stroh EL,Besa PC,Cox JD,et al. Treatment of patients with lymphomas of the uterus or cervix with combination chemotherapy and radiation therapy[J].Cancer,1995,75(9):2392-2399.
2018, Vol. 27 
